Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698891 · ClinicalTrials.gov registry record · Phase 2
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
A Phase 2 study of Early Stage Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
- 4
- Study locations
NCT02698891: Completed Phase 2 study of Early Stage Breast Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02698891 is a Phase 2 study of Early Stage Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 127 participants, below the 408-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02698891, a Phase 2 study of Early Stage Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support. The research study is for participants who have early stage breast cancer and have been recommended to receive a standard chemotherapy regimen, doxorubicin/cyclophosphamide (AC) plus Paclitaxel (T), in what is called a "dose-dense" fashion to prevent recurrences.
Primary Outcome
Rate of participants who completed Paclitaxel treatment in 7 weeks while omitting Neulasta™ (Pegfilgrastim). Neulasta is administered based on the following pre-specified safety criteria. * The patient experiences a prior episode of fever and neutropenia. * If the patient has an active infection this decision will be at provider discretion.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Neulasta
Study Locations (4)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Dana-Farber at Milford Regional Cancer Center - Milford
- Dana-Farber Cancer Institute at South Shore - Weymouth
New Hampshire
- Dana-Farber/New Hampshire Oncology-Hematology - Londonderry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2021-11 |
| Phase | Phase 2 |
What the finished NCT02698891 record still lists
NCT02698891 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 408-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02698891 reports a single indexed study location in Massachusetts, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02698891 about?
NCT02698891 is a clinical study titled "Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer". This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support. The research study is for participants who have early stage breast cancer and have b...
What is the current status of trial NCT02698891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2016-04-07. Estimated completion is 2021-11.
What conditions does trial NCT02698891 study?
This clinical trial studies the following conditions: Early Stage Breast Cancer.
What interventions are being tested in trial NCT02698891?
The interventions under investigation include: Paclitaxel (DRUG), Neulasta (DRUG).
Who is sponsoring clinical trial NCT02698891?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02698891 being conducted?
This trial has 4 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02698891's enrollment target sits among peer trials
127 6th of 21 higher than 16 of 21 other Early Stage Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Stage Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI